News

The alliance between the two companies was created to select specific proteins which can be manufactured into drugs that either have received orphan drug designation or have the

Israel-based Teva Pharmaceuticals, Iceland’s Actavis, US-based Mylan Laboratories and Indian companies Cipla and Ranbaxy have all made bids, according to reports carried by the Reuters news agency. However,

Ortho-McNeil entered into a collaboration and license agreement with Cellzome in May 2005 and the collaboration was extended for a further year in January 2007. The milestone payment

The program contains a number of development candidates targeting TLRs to activate innate immunity. VentiRx expects to develop its first two candidates in oncology and allergy. Array will

The study, being conducted at UCSF Medical Center, is enrolling HIV-1 infected subjects with compromised CD4+ cell counts, to determine whether the procedure will create sufficient HIV-1 resistant

Oxford BioMedica said that Oxxon's technology has broad product applications in cancer and infectious diseases and will create new licensing opportunities. Oxxon's lead cancer vaccine, Hi-8 MEL, has

A vaccine for ricin is considered by many the best way to prospectively protect certain human populations who are at risk of exposure. Since this vaccine would presumably

Tyrima is a member of a novel class of drugs known as reversible inhibitors of monoamine oxidase A, or RIMAs. The single-dose, placebo-controlled trial evaluated Tyrima in 41

Phase I clinical trials with anatibant in healthy volunteers and patients with TBI demonstrated a favorable clinical safety, tolerability and pharmokinetic profile, according to the company. Xytis plans